Orion Corporation upgrades the full-year outlook estimate for 2012 provided in the Financial Statement Release 2011 and published on 7 February 2012. The company estimates that the full-year net sales and operating profit will be higher than estimated in the previous outlook.
New full-year outlook estimate for 2012, provided on 3 July 2012
Net sales will be slightly higher than in 2011.
Operating profit will be slightly higher than in 2010.
The Group's capital expenditure will be about EUR 50 million excluding substantial corporate or product acquisitions.
Previous full-year outlook for 2012, provided in Financial Statement Release 2011
Net sales will be at similar level to 2011.
Operating profit will be at similar level to 2010.
The Group's capital expenditure will be about EUR 50 million excluding substantial corporate or product acquisitions.
Orion will publish the Interim Report January-June 2012 on Tuesday, 31 July 2012.
Orion Corporation
| Timo Lappalainen President and CEO | Olli Huotari SVP, Corporate Functions |
Contact person:
Jari Karlson, CFO, tel. +358 050 966 2883
Publisher:
Orion Corporation
Communications
Orionintie 1A, FI-02200 Espoo
www.orion.fi
Orion is a globally operating Finnish company developing pharmaceuticals and diagnostic tests - a builder of well-being. Orion develops, manufactures and markets human and veterinary pharmaceuticals, active pharmaceutical ingredients and diagnostic tests. The company is continuously developing new drugs and treatment methods. Pharmaceutical R&D focuses on central nervous system drugs, oncology and critical care drugs, and Easyhaler® pulmonary drugs.
Orion's net sales in 2011 amounted to EUR 918 million and the company had about 3,400 employees. Orion's A and B shares are listed on NASDAQ OMX Helsinki.